🇺🇸 FDA
Pipeline program

AXS-05 (dextromethorphan-bupropion)

AXS-05-TRD-202

Phase 2 small_molecule terminated

Quick answer

AXS-05 (dextromethorphan-bupropion) for Treatment Resistant Depression is a Phase 2 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Axsome Therapeutics
Indication
Treatment Resistant Depression
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials